Kodiak Sciences recruiting Phase 3 ALTO trial testing tabirafusp tedromer vs. aflibercept in DME
Kodiak Sciences has opened enrollment for a Phase 3 study comparing its investigational eye drug tabirafusp tedromer to aflibercept in diabetic macular edema patients.
Kodiak Sciences had one registry update this week involving a Phase 3 diabetic eye disease trial.
- Kodiak Sciences is recruiting for "ALTO," a Phase 3 trial comparing intravitreal tabirafusp tedromer 5 mg against intravitreal aflibercept 2 mg in participants with visual impairment secondary to diabetic macular edema.1 The study is enrolling an estimated 910 participants, with a primary completion date estimated for August 31, 2028.1 The trial's primary outcome measure is mean change in best corrected visual acuity (BCVA) from Day 1 to Year 1, assessed at Week 52.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.